View ValuationAmoy Diagnostics 향후 성장Future 기준 점검 1/6Amoy Diagnostics (는) 각각 연간 14.6% 및 12.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.5% 로 예상됩니다.핵심 정보14.6%이익 성장률15.97%EPS 성장률Biotechs 이익 성장27.6%매출 성장률12.7%향후 자기자본이익률18.47%애널리스트 커버리지Good마지막 업데이트01 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 30Amoy Diagnostics Co., Ltd. to Report First Half, 2026 Results on Jul 31, 2026Amoy Diagnostics Co., Ltd. announced that they will report first half, 2026 results on Jul 31, 2026Valuation Update With 7 Day Price Move • Jun 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥17.20, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 24x in the Biotechs industry in China. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.39 per share.Board Change • Jun 08Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Qiao Wu was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Director Qiao Wu was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 16Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China공시 • Mar 31Amoy Diagnostics Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026공시 • Dec 31Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026공시 • Oct 27Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 34.5 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will used to cancel and reduce the company's registered capital. The authorization will be valid for 12 months.공시 • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025공시 • Jul 02Amoy Diagnostics Co., Ltd. to Report First Half, 2025 Results on Jul 29, 2025Amoy Diagnostics Co., Ltd. announced that they will report first half, 2025 results on Jul 29, 2025공시 • Apr 23Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2024Amoy Diagnostics Co., Ltd. proposed final cash dividend/10 shares (tax included) of CNY3.00000000 for the year 2024.공시 • Apr 22Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China공시 • Mar 31Amoy Diagnostics Co., Ltd. to Report Q1, 2025 Results on Apr 22, 2025Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2025 results on Apr 22, 2025공시 • Dec 31Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2024 Results on Apr 22, 2025Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2024 results on Apr 22, 2025Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.12 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.21 (up from CN¥0.12 in 3Q 2023). Revenue: CN¥305.0m (up 23% from 3Q 2023). Net income: CN¥83.4m (up 78% from 3Q 2023). Profit margin: 27% (up from 19% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 35%After last week's 35% share price gain to CN¥24.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 45% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.05 per share.공시 • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2024 results on Oct 22, 2024Buy Or Sell Opportunity • Sep 18Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at CN¥18.30. The fair value is estimated to be CN¥22.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 55% in the next 2 years.공시 • Aug 16Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent DirectorAmoy Diagnostics Co., Ltd. at the Extraordinary General Meeting of 2024 on 14 August 2024 approved election and nomination of independent directors, cumulative voting system applicable: Shen Zhe, independent director; Wu Qiao, independent director.Buy Or Sell Opportunity • Aug 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to CN¥18.42. The fair value is estimated to be CN¥23.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 54% in the next 2 years.Reported Earnings • Jul 31Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.18 in 2Q 2023). Revenue: CN¥309.7m (up 18% from 2Q 2023). Net income: CN¥79.7m (up 15% from 2Q 2023). Profit margin: 26% (in line with 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jul 04Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to CN¥17.51. The fair value is estimated to be CN¥22.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has grown by 8.3%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 52% in the next 2 years.공시 • Jun 29Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024Amoy Diagnostics Co., Ltd. announced that they will report first half, 2024 results on Jul 30, 2024Declared Dividend • May 27Dividend increased to CN¥0.15Dividend of CN¥0.15 is 7.1% higher than last year. Ex-date: 30th May 2024 Payment date: 30th May 2024 Dividend yield will be 0.8%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 20% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • May 25Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024Amoy Diagnostics Co., Ltd. announced final cash dividend of CNY 1.50000000 per ten A shares (tax included) for the year 2023. Record date: 29 May 2024. Ex-date: 30 May 2024. Payment date: 30 May 2024.Reported Earnings • Apr 19Full year 2023 earnings released: EPS: CN¥0.66 (vs CN¥0.67 in FY 2022)Full year 2023 results: EPS: CN¥0.66 (down from CN¥0.67 in FY 2022). Revenue: CN¥1.04b (up 24% from FY 2022). Net income: CN¥261.5m (flat on FY 2022). Profit margin: 25% (down from 31% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.공시 • Apr 16Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China공시 • Apr 02Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.Amoy Diagnostics Co., Ltd. (SZSE:300685) commences share repurchases on March 29, 2024, under the program mandated by shareholders in the Extraordinary General Meeting held on February 26, 2024. As per the mandate, the company is authorized to repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 28 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will use its own fund to fund the repurchase. The authorization will be valid for 12 months.공시 • Mar 30Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2024 results on Apr 23, 2024Buy Or Sell Opportunity • Feb 27Now 24% overvaluedOver the last 90 days, the stock has fallen 4.4% to CN¥21.30. The fair value is estimated to be CN¥17.21, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 57% in 2 years. Earnings are forecast to grow by 74% in the next 2 years.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥19.68, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.23 per share.New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin).공시 • Dec 29Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2023 results on Apr 16, 2024공시 • Dec 13+ 1 more updateAmoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component IndexAmoy Diagnostics Co., Ltd. has been removed from Shenzhen Stock Exchange Component Index .New Risk • Oct 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 22% Last year net profit margin: 33% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (22% net profit margin).공시 • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2023 results on Oct 24, 2023Reported Earnings • Aug 01Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.087 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.18 (up from CN¥0.087 in 2Q 2022). Revenue: CN¥263.5m (up 41% from 2Q 2022). Net income: CN¥69.4m (up 95% from 2Q 2022). Profit margin: 26% (up from 19% in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.공시 • Jul 01Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023Amoy Diagnostics Co., Ltd. announced that they will report first half, 2023 results on Aug 01, 2023공시 • May 17Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023Amoy Diagnostics Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 1.40000000. Record date: 22 May 2023, Ex-date: 23 May 2023 and Payment date: 23 May 2023. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.14000000(10% x CNY1.40000000) Net cash dividend/10 shares after tax: CNY1.26000000(CNY1.40000000- CNY0.14000000).Reported Earnings • Apr 15Full year 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.67 (up from CN¥0.61 in FY 2021). Revenue: CN¥842.2m (down 8.2% from FY 2021). Net income: CN¥263.7m (up 10% from FY 2021). Profit margin: 31% (up from 26% in FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 3 highly experienced directors. 4 independent directors (5 non-independent directors). Chairman Li-Mou Zheng is the most experienced director on the board, commencing their role in 2008. Non-Independent Director Xin Huang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 25Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.35 (up from CN¥0.16 in 3Q 2021). Revenue: CN¥206.8m (down 16% from 3Q 2021). Net income: CN¥134.9m (up 107% from 3Q 2021). Profit margin: 65% (up from 26% in 3Q 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥25.19, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 8.7% over the past three years.Reported Earnings • Jul 31Second quarter 2022 earnings released: EPS: CN¥0.087 (vs CN¥0.17 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.087 (down from CN¥0.17 in 2Q 2021). Revenue: CN¥186.5m (down 17% from 2Q 2021). Net income: CN¥35.7m (down 48% from 2Q 2021). Profit margin: 19% (down from 30% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 44%, compared to a 36% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 19% per year.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥34.93, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 33x in the Biotechs industry in China. Total returns to shareholders of 81% over the past three years.Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Deputy GM, Secretary of the Board of Directors & Non-Independent Director Jiemin Luo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 13Full year 2021 earnings released: EPS: CN¥1.09 (vs CN¥0.82 in FY 2020)Full year 2021 results: EPS: CN¥1.09 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥239.6m (up 33% from FY 2020). Profit margin: 26% (up from 25% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 49% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Buying Opportunity • Apr 09Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be CN¥60.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 71% in 2 years. Earnings is forecast to grow by 83% in the next 2 years.Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥1.05 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥231.4m (up 28% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue missed analyst estimates by 3.5%. Over the next year, revenue is forecast to grow 36%, compared to a 43% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥246.8m (up 23% from 3Q 2020). Net income: CN¥65.2m (up 44% from 3Q 2020). Profit margin: 26% (up from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jul 26Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥225.2m (up 17% from 2Q 2020). Net income: CN¥67.9m (up 24% from 2Q 2020). Profit margin: 30% (up from 28% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 14Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥728.4m (up 26% from FY 2019). Net income: CN¥180.3m (up 34% from FY 2019). Profit margin: 25% (up from 23% in FY 2019). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Mar 10New 90-day low: CN¥67.96The company is down 13% from its price of CN¥77.73 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.12 per share.Is New 90 Day High Low • Feb 09New 90-day high: CN¥92.11The company is up 17% from its price of CN¥78.85 on 11 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥31.05 per share.Is New 90 Day High Low • Jan 22New 90-day high: CN¥87.26The company is up 10.0% from its price of CN¥79.00 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥27.80 per share.Is New 90 Day High Low • Dec 22New 90-day low: CN¥71.91The company is down 5.0% from its price of CN¥75.85 on 24 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥27.59 per share.Is New 90 Day High Low • Nov 27New 90-day low: CN¥72.29The company is down 18% from its price of CN¥88.26 on 28 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥24.49 per share.Reported Earnings • Oct 21Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥152.2m, up 9.0% from the prior year. Total revenue was CN¥649.9m over the last 12 months, up 20% from the prior year.이익 및 매출 성장 예측XSEC:300685 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,672533N/A509312/31/20271,586487390444612/31/20261,40142532039863/31/20261,186356297369N/A12/31/20251,198361295365N/A9/30/20251,127290308377N/A6/30/20251,145300321373N/A3/31/20251,148281321365N/A12/31/20241,109255302342N/A9/30/20241,184315289324N/A6/30/20241,128279262295N/A3/31/20241,082268274312N/A12/31/20231,044261254299N/A9/30/2023951213222269N/A6/30/2023908301164222N/A3/31/2023831267108189N/A1/1/202384226471149N/A9/30/202287128775140N/A6/30/202291121881146N/A3/31/202294925088134N/A1/1/202291724094168N/A9/30/2021890231107196N/A6/30/2021844211125224N/A3/31/2021811198143235N/A12/31/2020728180163221N/A9/30/2020650153114167N/A6/30/2020595138126159N/A3/31/2020550129143170N/A12/31/2019578135N/A152N/A9/30/2019541140N/A153N/A6/30/2019502135N/A120N/A3/31/2019469134N/A104N/A12/31/2018439127N/A93N/A9/30/2018398122N/A108N/A6/30/2018384120N/A114N/A3/31/2018357103N/A96N/A12/31/201733094N/A92N/A9/30/201731582N/A70N/A6/30/201728878N/A49N/A3/31/201725867N/A40N/A12/31/201625367N/A32N/A6/30/201622042N/A24N/A3/31/201619832N/A22N/A12/31/201517721N/A19N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 300685 의 연간 예상 수익 증가율(14.6%)이 saving rate(2.4%)보다 높습니다.수익 vs 시장: 300685 의 연간 수익(14.6%)이 CN 시장(27.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 300685 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 300685 의 수익(연간 12.7%)이 CN 시장(연간 16.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 300685 의 수익(연간 12.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 300685의 자본 수익률은 3년 후 18.5%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/08 06:17종가2026/07/08 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Amoy Diagnostics Co., Ltd.는 14명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Pei ChengChina Galaxy Securities Co., Ltd.Jin ZhangChina International Capital Corporation LimitedZiyu HeChina International Capital Corporation Limited11명의 분석가 더 보기
공시 • Jun 30Amoy Diagnostics Co., Ltd. to Report First Half, 2026 Results on Jul 31, 2026Amoy Diagnostics Co., Ltd. announced that they will report first half, 2026 results on Jul 31, 2026
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥17.20, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 24x in the Biotechs industry in China. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.39 per share.
Board Change • Jun 08Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Qiao Wu was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Director Qiao Wu was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 16Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China
공시 • Mar 31Amoy Diagnostics Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026
공시 • Dec 31Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026
공시 • Oct 27Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 34.5 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will used to cancel and reduce the company's registered capital. The authorization will be valid for 12 months.
공시 • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025
공시 • Jul 02Amoy Diagnostics Co., Ltd. to Report First Half, 2025 Results on Jul 29, 2025Amoy Diagnostics Co., Ltd. announced that they will report first half, 2025 results on Jul 29, 2025
공시 • Apr 23Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2024Amoy Diagnostics Co., Ltd. proposed final cash dividend/10 shares (tax included) of CNY3.00000000 for the year 2024.
공시 • Apr 22Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China
공시 • Mar 31Amoy Diagnostics Co., Ltd. to Report Q1, 2025 Results on Apr 22, 2025Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2025 results on Apr 22, 2025
공시 • Dec 31Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2024 Results on Apr 22, 2025Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2024 results on Apr 22, 2025
Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.12 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.21 (up from CN¥0.12 in 3Q 2023). Revenue: CN¥305.0m (up 23% from 3Q 2023). Net income: CN¥83.4m (up 78% from 3Q 2023). Profit margin: 27% (up from 19% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 35%After last week's 35% share price gain to CN¥24.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 45% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.05 per share.
공시 • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2024 results on Oct 22, 2024
Buy Or Sell Opportunity • Sep 18Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at CN¥18.30. The fair value is estimated to be CN¥22.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 55% in the next 2 years.
공시 • Aug 16Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent DirectorAmoy Diagnostics Co., Ltd. at the Extraordinary General Meeting of 2024 on 14 August 2024 approved election and nomination of independent directors, cumulative voting system applicable: Shen Zhe, independent director; Wu Qiao, independent director.
Buy Or Sell Opportunity • Aug 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to CN¥18.42. The fair value is estimated to be CN¥23.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 54% in the next 2 years.
Reported Earnings • Jul 31Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.18 in 2Q 2023). Revenue: CN¥309.7m (up 18% from 2Q 2023). Net income: CN¥79.7m (up 15% from 2Q 2023). Profit margin: 26% (in line with 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jul 04Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to CN¥17.51. The fair value is estimated to be CN¥22.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has grown by 8.3%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 52% in the next 2 years.
공시 • Jun 29Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024Amoy Diagnostics Co., Ltd. announced that they will report first half, 2024 results on Jul 30, 2024
Declared Dividend • May 27Dividend increased to CN¥0.15Dividend of CN¥0.15 is 7.1% higher than last year. Ex-date: 30th May 2024 Payment date: 30th May 2024 Dividend yield will be 0.8%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 20% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • May 25Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024Amoy Diagnostics Co., Ltd. announced final cash dividend of CNY 1.50000000 per ten A shares (tax included) for the year 2023. Record date: 29 May 2024. Ex-date: 30 May 2024. Payment date: 30 May 2024.
Reported Earnings • Apr 19Full year 2023 earnings released: EPS: CN¥0.66 (vs CN¥0.67 in FY 2022)Full year 2023 results: EPS: CN¥0.66 (down from CN¥0.67 in FY 2022). Revenue: CN¥1.04b (up 24% from FY 2022). Net income: CN¥261.5m (flat on FY 2022). Profit margin: 25% (down from 31% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
공시 • Apr 16Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China
공시 • Apr 02Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.Amoy Diagnostics Co., Ltd. (SZSE:300685) commences share repurchases on March 29, 2024, under the program mandated by shareholders in the Extraordinary General Meeting held on February 26, 2024. As per the mandate, the company is authorized to repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 28 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will use its own fund to fund the repurchase. The authorization will be valid for 12 months.
공시 • Mar 30Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2024 results on Apr 23, 2024
Buy Or Sell Opportunity • Feb 27Now 24% overvaluedOver the last 90 days, the stock has fallen 4.4% to CN¥21.30. The fair value is estimated to be CN¥17.21, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 57% in 2 years. Earnings are forecast to grow by 74% in the next 2 years.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥19.68, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.23 per share.
New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin).
공시 • Dec 29Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2023 results on Apr 16, 2024
공시 • Dec 13+ 1 more updateAmoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component IndexAmoy Diagnostics Co., Ltd. has been removed from Shenzhen Stock Exchange Component Index .
New Risk • Oct 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 22% Last year net profit margin: 33% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (22% net profit margin).
공시 • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2023 results on Oct 24, 2023
Reported Earnings • Aug 01Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.087 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.18 (up from CN¥0.087 in 2Q 2022). Revenue: CN¥263.5m (up 41% from 2Q 2022). Net income: CN¥69.4m (up 95% from 2Q 2022). Profit margin: 26% (up from 19% in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
공시 • Jul 01Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023Amoy Diagnostics Co., Ltd. announced that they will report first half, 2023 results on Aug 01, 2023
공시 • May 17Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023Amoy Diagnostics Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 1.40000000. Record date: 22 May 2023, Ex-date: 23 May 2023 and Payment date: 23 May 2023. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.14000000(10% x CNY1.40000000) Net cash dividend/10 shares after tax: CNY1.26000000(CNY1.40000000- CNY0.14000000).
Reported Earnings • Apr 15Full year 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.67 (up from CN¥0.61 in FY 2021). Revenue: CN¥842.2m (down 8.2% from FY 2021). Net income: CN¥263.7m (up 10% from FY 2021). Profit margin: 31% (up from 26% in FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 3 highly experienced directors. 4 independent directors (5 non-independent directors). Chairman Li-Mou Zheng is the most experienced director on the board, commencing their role in 2008. Non-Independent Director Xin Huang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 25Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.35 (up from CN¥0.16 in 3Q 2021). Revenue: CN¥206.8m (down 16% from 3Q 2021). Net income: CN¥134.9m (up 107% from 3Q 2021). Profit margin: 65% (up from 26% in 3Q 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥25.19, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 8.7% over the past three years.
Reported Earnings • Jul 31Second quarter 2022 earnings released: EPS: CN¥0.087 (vs CN¥0.17 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.087 (down from CN¥0.17 in 2Q 2021). Revenue: CN¥186.5m (down 17% from 2Q 2021). Net income: CN¥35.7m (down 48% from 2Q 2021). Profit margin: 19% (down from 30% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 44%, compared to a 36% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 19% per year.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥34.93, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 33x in the Biotechs industry in China. Total returns to shareholders of 81% over the past three years.
Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Deputy GM, Secretary of the Board of Directors & Non-Independent Director Jiemin Luo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 13Full year 2021 earnings released: EPS: CN¥1.09 (vs CN¥0.82 in FY 2020)Full year 2021 results: EPS: CN¥1.09 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥239.6m (up 33% from FY 2020). Profit margin: 26% (up from 25% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 49% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Buying Opportunity • Apr 09Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be CN¥60.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 71% in 2 years. Earnings is forecast to grow by 83% in the next 2 years.
Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥1.05 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥231.4m (up 28% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue missed analyst estimates by 3.5%. Over the next year, revenue is forecast to grow 36%, compared to a 43% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥246.8m (up 23% from 3Q 2020). Net income: CN¥65.2m (up 44% from 3Q 2020). Profit margin: 26% (up from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jul 26Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥225.2m (up 17% from 2Q 2020). Net income: CN¥67.9m (up 24% from 2Q 2020). Profit margin: 30% (up from 28% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 14Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥728.4m (up 26% from FY 2019). Net income: CN¥180.3m (up 34% from FY 2019). Profit margin: 25% (up from 23% in FY 2019). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Mar 10New 90-day low: CN¥67.96The company is down 13% from its price of CN¥77.73 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.12 per share.
Is New 90 Day High Low • Feb 09New 90-day high: CN¥92.11The company is up 17% from its price of CN¥78.85 on 11 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥31.05 per share.
Is New 90 Day High Low • Jan 22New 90-day high: CN¥87.26The company is up 10.0% from its price of CN¥79.00 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥27.80 per share.
Is New 90 Day High Low • Dec 22New 90-day low: CN¥71.91The company is down 5.0% from its price of CN¥75.85 on 24 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥27.59 per share.
Is New 90 Day High Low • Nov 27New 90-day low: CN¥72.29The company is down 18% from its price of CN¥88.26 on 28 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥24.49 per share.
Reported Earnings • Oct 21Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥152.2m, up 9.0% from the prior year. Total revenue was CN¥649.9m over the last 12 months, up 20% from the prior year.